Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T94309
|
||||
Former ID |
TTDC00295
|
||||
Target Name |
Triacylglycerol lipase, pancreatic
|
||||
Gene Name |
PNLIP
|
||||
Synonyms |
PL; Pancreatic lipase; PNLIP
|
||||
Target Type |
Successful
|
||||
Disease | Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99] | ||||
Cystic fibrosis [ICD9: 277; ICD10: E84] | |||||
Exocrine pancreatic insufficiency [ICD10: K86.8] | |||||
Obesity [ICD9: 278; ICD10: E66] | |||||
Pancreatic disease [ICD10: K85-K86] | |||||
BioChemical Class |
Carboxylic ester hydrolase
|
||||
Target Validation |
T94309
|
||||
UniProt ID | |||||
EC Number |
EC 3.1.1.3
|
||||
Sequence |
MLPLWTLSLLLGAVAGKEVCYERLGCFSDDSPWSGITERPLHILPWSPKDVNTRFLLYTN
ENPNNFQEVAADSSSISGSNFKTNRKTRFIIHGFIDKGEENWLANVCKNLFKVESVNCIC VDWKGGSRTGYTQASQNIRIVGAEVAYFVEFLQSAFGYSPSNVHVIGHSLGAHAAGEAGR RTNGTIGRITGLDPAEPCFQGTPELVRLDPSDAKFVDVIHTDGAPIVPNLGFGMSQVVGH LDFFPNGGVEMPGCKKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPDGFAGF PCASYNVFTANKCFPCPSGGCPQMGHYADRYPGKTNDVGQKFYLDTGDASNFARWRYKVS VTLSGKKVTGHILVSLFGNKGNSKQYEIFKGTLKPDSTHSNEFDSDVDVGDLQMVKFIWY NNVINPTLPRVGASKIIVETNVGKQFNFCSPETVREEVLLTLTPC |
||||
Drugs and Mode of Action | |||||
Drug(s) | Dalbavancin | Drug Info | Approved | Bacterial infections | [533123], [551871] |
Orlistat | Drug Info | Approved | Obesity | [535886], [540740] | |
Pancrecarb | Drug Info | NDA filed | Pancreatic disease | [550604] | |
Liprotamase | Drug Info | Phase 3 | Cystic fibrosis | [522063] | |
MS-1819 | Drug Info | Phase 1/2 | Exocrine pancreatic insufficiency | [548921] | |
AZM-131 | Drug Info | Terminated | Obesity | [546516] | |
Inhibitor | (Hydroxyethyloxy)Tri(Ethyloxy)Octane | Drug Info | [551393] | ||
B-Nonylglucoside | Drug Info | [551374] | |||
B-Octylglucoside | Drug Info | [551393] | |||
Daio-Orengedokuto (DOT) | Drug Info | [535601] | |||
Dalbavancin | Drug Info | [536589], [549974] | |||
METHOXYUNDECYLPHOSPHINIC ACID | Drug Info | [551374] | |||
Modulator | AZM-131 | Drug Info | [550117] | ||
Liprotamase | Drug Info | [549848] | |||
MS-1819 | Drug Info | [550329] | |||
Orlistat | Drug Info | [556264] | |||
Pancrecarb | Drug Info | [550604] | |||
Pathways | |||||
BioCyc Pathway | Triacylglycerol degradation | ||||
Retinol biosynthesis | |||||
KEGG Pathway | Glycerolipid metabolism | ||||
Metabolic pathways | |||||
Pancreatic secretion | |||||
Fat digestion and absorption | |||||
Vitamin digestion and absorption | |||||
Reactome | Retinoid metabolism and transport | ||||
WikiPathways | Visual phototransduction | ||||
Lipid digestion, mobilization, and transport | |||||
References | |||||
Ref 522063 | ClinicalTrials.gov (NCT00500084) Phase III ALTU-135 CP Safety Trial. U.S. National Institutes of Health. | ||||
Ref 535886 | Obesity and pharmacologic therapy. Endocrinol Metab Clin North Am. 2003 Dec;32(4):1005-24. | ||||
Ref 540740 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5277). | ||||
Ref 546516 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008694) | ||||
Ref 535601 | Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase. Biol Pharm Bull. 2002 Nov;25(11):1442-5. | ||||
Ref 536589 | Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis. 2008 Feb 15;46(4):577-83. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.